Gene

CTAG2

cancer/testis antigen 2

Explore in graph →CI-GENE-00042454HGNC:2492 ENSG00000126890 NCBI 30848 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CTAG2 Overexpression1
Letetresgene Autoleucel	Multiple Myeloma	Predictive	B	Supports Sensitivity Response	3	accepted	EID2941 Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing … (full text at CIViC) PMID 26193344 · Rapoport et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Adenoid Cystic Carcinoma (MSK, Nat Genet 2013) acyc_mskcc_2013	Adenoid Cystic Carcinoma	Ssm	1	60

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
· Nat Med · 2015 · PMID 26193344 · validated civic_curation pubmed